New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
09:11 EDTA, ABTAgilent unit says white paper supports superiority of HER2 IQFISH pharmDx kit
Dako, an Agilent Technologies (A) company, announced positive findings in a white paper by ProPath Services, an independent anatomic pathology laboratory, comparing Dako's HER2 IQFISH pharmDx kit with Abbott's (ABT) PathVysion HER-2 DNA Probe kit. "The authors found that HER2 IQFISH pharmDxTM provided better overall quality than the PathVysion kit, defined by better signal-to-background ratio enabling more accurate determination of copy numbers. The study also concluded that the Dako kit saved 30-60 minutes of hands-on time per slide, due to less hands-on time required by lab staff, and reduced time required by the pathologist for reading and scoring," Dako said.
News For A;ABT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:18 EDTAAgilent risk/reward favorable into spin-off, says Leerink
Subscribe for More Information
08:18 EDTAAgilent risk/reward favorable into spin-off, says Leerink
Subscribe for More Information
September 29, 2014
16:20 EDTAAgilent says regulatory authorities close past FCPA probe
Agilent disclosed in a filing that on September 6, 2013, Agilent Technologies disclosed in its Form 10-Q that it had initiated an internal investigation relating to certain sales of company products through third party intermediaries in China and compliance by company employees in China with the requirements of the U.S. Foreign Corrupt Practices Act and other applicable laws and regulations. The company further disclosed that it had voluntarily advised the United States Department of Justice and the United States Securities and Exchange Commission of the investigation. On September 15, the company received a letter from the SEC’s Division of Enforcement stating that its investigation had been completed and that the Division of Enforcement did not intend to recommend any enforcement action against the company by the SEC. On September 24, the company received a letter from DOJ stating that DOJ had closed its inquiry into the matter, citing the company’s voluntary disclosure and thorough investigation.
11:02 EDTAAgilent announces collaboration with University of Toronto
Agilent announced a collaboration with scientists at the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research to produce a comprehensive metabolomics multiple-reaction monitoring library and methodology, using Agilent’s Infinity 1290 UHPLC and 6460 triple quadrupole mass spectrometry system.
September 26, 2014
09:01 EDTABTAbbott completes CFR Pharmaceuticals acquisition
Abbott has acquired control of CFR Pharmaceuticals, doubling its Latin American branded generics pharmaceutical presence and further expanding the company's presence in fast-growing markets. Through purchase of the controlling interest and tender offers described below, Abbott indirectly acquired more than 99% of CFR's ordinary shares for approximately $2.9B. The CFR acquisition immediately establishes Abbott among the top 10 pharmaceutical companies in Latin America, a market that is expected to reach $124B by 2018, with estimated annual growth rates of two to three times that of developed markets over the coming years, according to IMS. This transaction will not impact Abbott's ongoing earnings-per-share guidance for 2014. Abbott anticipates this transaction to be accretive to ongoing earnings per share in 2015 and increasing thereafter, before one-time transaction-related items which will be provided at a later date.
07:22 EDTAAgilent management to meet with Jefferies
Meeting to be held in the Mid-Atlantic area on October 2 hosted by Jefferies.
September 24, 2014
09:03 EDTABTAbbott's U.S. tender offer for Chile's CFR Pharmaceuticals expired
Abbott announced the expiration of the tender offer for the purchase from U.S. holders of the ordinary shares of CFR Pharmaceuticals S.A., a Chilean corporation, and for the purchase from all holders, wherever resident, of CFR's outstanding ADS. The offer expired at 5 p.m., NYC time, on Sept. 23, and was not extended. A Chilean tender offer for CFR ordinary shares, which was made concurrently with the U.S. offer, expired at 5:30 p.m., Chilean time, on Sept. 23, and was not extended. The results of the U.S. offer will be announced on Sept. 26, at the time the results of the Chilean tender offer for CFR ordinary shares are announced.
06:23 EDTABTExperts see new tax rules not halting inversions, WSJ reports
Subscribe for More Information
September 23, 2014
10:54 EDTABTStocks, analysts react to Treasury inversion crackdown
Subscribe for More Information
09:13 EDTABTOn The Fly: Pre-market Movers
Subscribe for More Information
08:53 EDTABTInversion regulations look more onerous than expected, says FBR Capital
FBR Capital says the new regulations announced last night by the Treasury and IRS contain appear more onerous than expected. FBR points out the proposed changes remove the ability of inverting companies to make "hopscotch loans" between the foreign and domestic subsidiaries. The firm believes the regulations will not end the practice of inversions, and it still expects completion of already announced deals.
06:28 EDTABTTreasury rules may put Mylan deal at risk, says BMO Capital
BMO Capital believes Treasury's new inversion rules may put the tax benefits of Mylan's (MYL) planned acquisition of Abbott's (ABT) established products business at risk. BMO also thinks the rules impact Salix's (SLXP) pending deal for Cosmo Pharmaceuticals, which it feels may help make a deal with Allergan (AGN) more likely.
05:56 EDTABTTreasury, IRS announce plans to reduce inversion tax benefits
Subscribe for More Information
September 22, 2014
07:06 EDTABTAbbott price target raised to $48 from $44 at RBC Capital
Subscribe for More Information
September 19, 2014
11:25 EDTABTSenators bring bill requiring companies to settle before inverting
U.S. Senators Sherrod Brown and Dick Durbin announced new legislation requiring corporations to "Pay What You Owe Before You Go" – settling their U.S. tax bill before relocating to a foreign country. "Everyone knows that before you leave a restaurant you have to settle your tab," Brown said. "Corporations shouldn’t get to play by different rules. While it is critical that we reach a long-term solution that reforms our international corporate tax code by implementing a global minimum tax and reducing the statutory tax rate, this bill is an immediate, commonsense measure to ensure businesses settle up before leaving the U.S." Among the deals or possible transactions that involve inversion are Mylan's (MYL) acquisition of Abbott (ABT), Medtronic's (MDT) acquisition of Covidien (COV) and Valeant's (VRX) proposed takeover of Allergan (AGN).
September 17, 2014
18:29 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:01 EDTAAgilent board approves separation of Keysight, declares special dividend
Subscribe for More Information
16:57 EDTAAgilent creates new group for services, consumables
Subscribe for More Information
16:55 EDTAAgilent announces Mike McMullen to succeed Bill Sullivan as CEO in March 2015
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use